Navigation Links
Cephalon Completes Acquisition of Arana Therapeutics
Date:8/10/2009

ing development and capabilities; market prospects for its products; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.


    Contacts:

    Media:                                 Investor Relations:
    Sheryl Williams                        Chip Merritt
    610-738-6493 (office)                  610-738-6376 (office)
    610-457-5257 (cell)                    cmerritt@cephalon.com
    swilliam@cephalon.com


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2014)... The discovery 30 years ago of soccer-ball-shaped carbon molecules ... research. Now, there appears to be a new ball ... University and Tsinghua University in China have shown that ... molecular cage similar to a carbon buckyball. It,s the ... a matter of speculationdoes indeed exist. , "This is ...
(Date:7/13/2014)... Dallas, TX (PRWEB) July 13, 2014 ... Silver Industry” is a professional and in-depth study on ... Global and China. , The report provides a basic ... chain structure. Global market analysis and Chinese domestic market ... trends and competitive landscape of the market. A comparison ...
(Date:7/12/2014)... July 12, 2014 This ... reagents used in the life science industry. ... life science reagents market towards remarkable growth. ... and providers of life science reagents. , ... http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global life ...
(Date:7/11/2014)... July 11, 2014 /PRNewswire-iReach/ -- Maxim Peptide, a website ... are used solely in scientific experiments, is currently celebrating ... in business, Maxim Peptide, which was created by the ... new and updated website that now features a special ... been updated with fascinating articles about peptide research, including ...
Breaking Biology Technology:Researchers discover boron 'buckyball' 2Researchers discover boron 'buckyball' 32014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 22014 Nano Silver Industry in Global and China Regions Development Proposals Analysis Available at DeepResearchReports.com 3Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2
... Researchers in India have demonstrated that producing nanoscopic crystals of ... by the gut even if the drug is not soluble ... the medicinal drugs being developed by the pharmaceutical industry dissolve ... a major problem for administering such drugs as it means ...
... ANGELES, Oct. 6 Entertain and interact.  That,s ... . ( www.drfresh.com ), the creator of the ... company behind the successful revival of the ... http://photos.prnewswire.com/prnh/20101006/LA77977LOGO ) (Logo:   http://www.newscom.com/cgi-bin/prnh/20101006/LA77977LOGO ) ...
... Inc. Against the Company And Certain of Its Subsidiaries ... ... --> ... var s = ,; var first_result; // Results are keyed by longUrl, so we need to ...
Cached Biology Technology:Nano drugs 2A 'Fresh' Approach to Marketing: Dr. Fresh™, Inc. Goes Guerilla With Internet-Based Campaigns 2Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 2Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 3Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 4Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 5Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 6Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 7Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 8Angiotech Pharmaceuticals, Inc. Announces Commencement of Arbitration and Litigation Proceedings by QSR Holdings, Inc. Against the Company And Certain of Its Subsidiaries 9
(Date:7/13/2014)... New research raises the prospect of more effective ... muscle occurring in about half of all cancer patients, ... Dana-Farber Cancer Institute. , Many strategies have been tried ... that patients can,t endure potentially life-saving treatments, but none ... July 13 advanced online edition of Nature , ...
(Date:7/11/2014)... Society shows that no-take zones in Belize can ... lobster, conch, and fish recover from overfishing, but ... The reporttitled "Review of the Benefits of No-Take ... no-take areas around the world. The report was ... in marine protected areas and fisheries management. The ...
(Date:7/11/2014)... at the Department of Energy,s Oak Ridge National ... by R&D Magazine in recognition of the year,s ... the tremendous value of our National Labs," said ... at the National Labs continues to help our ... scientific and technological innovations necessary to remain globally ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... and under-diagnosed genetic disease in humans just may be ... College of Georgia researchers report. They are pursuing a ... wet form of macular degeneration, the leading cause of blindness ... iron, known to wreak cumulative havoc on the body,s organs, ...
... the tenth anniversary of the completion of the first draft of ... to complete the Wellcome Trust today launches a project to ... This will be one of the largest genome sequencing programmes ever ... in 6,000 people in the UK. The UK10K project is ...
... in German . , Missour/Leipzig. In ... African bird species with a very distinctive courtship behaviour, ... of the same species positively affects brooding females, improving ... birds in the experiment were more fertile and had ...
Cached Biology News:Link between iron overload and macular degeneration under study 2Link between iron overload and macular degeneration under study 3Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 2Ten years on, Wellcome Trust launches study of 10,000 human genomes in UK 3Pleasing to the eye 2Pleasing to the eye 3
... CTI Molecular Imaging's proprietary Focus™ detector ... and a large imaging volume that ... image multiple mice or large primateswithout ... dedicated small animal PET (Positron Emission ...
...
These 18x18 square No.1 Corning cover glasses are made from No. 0211 zinc titania glass and are 0.16 to 0.19mm thick....
...
Biology Products: